Table 2 |
||||
|
Associations between CYP17 genetic polymorphisms and breast cancer by menopausal status: Western New York Breast Cancer Study |
||||
|
Case (n [%]) |
Control (n [%]) |
Crude odds ratio (95% CI) |
Adjusted odds ratio (95% CI)a |
|
|
|
||||
|
Premenopausal (n = 182) |
||||
|
A1/A1 |
58 (61) |
48 (56) |
1.00 |
1.00 |
|
A1/A2 |
31 (32) |
28 (33) |
0.92(0.48–1.73) |
0.85(0.44–1.63) |
|
A2/A2 |
7 (7) |
10 (11) |
0.58(0.21–1.64) |
0.56(0.20–1.62) |
|
Postmenopausal (n = 213) |
||||
|
A1/A1 |
51 (46) |
47 (46) |
1.00 |
1.00 |
|
A1/A2 |
52 (47) |
43 (42) |
1.10 (0.63–1.90) |
0.97 (0.45–2.20) |
|
A2/A2 |
8 (7) |
12 (12) |
0.60 (0.23–1.60) |
0.45 (0.13–1.60) |
|
|
||||
|
a Adjusted for age, education, family history of breast cancer, body mass index, and history of benign breast disease (and age at menopause in postmenopausal women). CI, confidence interval. |
||||
|
Ambrosone et al. Breast Cancer Res 2003 5:R45 doi:10.1186/bcr570 |
||||
